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OBJECTIVE — Dapagliﬂozin, a novel inhibitor of renal sodium-glucose cotransporter 2,
allows an insulin-independent approach to improve type 2 diabetes hyperglycemia. In this
multiple-dose study we evaluated the safety and efﬁcacy of dapagliﬂozin in type 2 diabetic
patients.
RESEARCH DESIGN AND METHODS — Type 2 diabetic patients were randomly
assigned to one of ﬁve dapagliﬂozin doses, metformin XR, or placebo for 12 weeks. The primary
objective was to compare mean change from baseline in A1C. Other objectives included com-
parison of changes in fasting plasma glucose (FPG), weight, adverse events, and laboratory
measurements.
RESULTS — After 12 weeks, dapagliﬂozin induced moderate glucosuria (52–85 g urinary
glucose/day) and demonstrated signiﬁcant glycemic improvements versus placebo (A1C
0.55 to 0.90% and FPG 16 to 31 mg/dl). Weight loss change versus placebo was 1.3
to 2.0 kg. There was no change in renal function. Serum uric acid decreased, serum magne-
siumincreased,serumphosphateincreasedathigherdoses,anddose-related24-hurinevolume
and hematocrit increased, all of small magnitude. Treatment-emergent adverse events were
similar across all groups.
CONCLUSIONS — Dapagliﬂozin improved hyperglycemia and facilitates weight loss in
type 2 diabetic patients by inducing controlled glucosuria with urinary loss of 200–300
kcal/day. Dapagliﬂozin treatment demonstrated no persistent, clinically signiﬁcant osmolarity,
volume, or renal status changes.
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T
ype 2 diabetes is characterized by
hyperglycemia, which contributes
to micro- and macrovascular com-
plications including retinopathy, ne-
phropathy, neuropathy, and accelerated
cardiovascular disease (1–4). Excess hy-
perglycemia promotes glucotoxicity
through increased insulin resistance and
interference with -cell function (5,6).
Despite various therapeutic options,
many patients demonstrate inadequate
glycemic control and remain at risk for
chronic complications (7).
Dapagliﬂozinistheﬁrstinanewclass
of oral selective sodium-glucose cotrans-
porter 2 (SGLT2) inhibitors designed for
treating type 2 diabetes (8,9). Dapagliﬂo-
zinimproveshyperglycemiabyinhibiting
renal glucose reabsorption through
SGLT2. SGLT2 is a sodium-solute co-
transport protein located in the kidney
proximal tubule that reabsorbs the ma-
jority of glomerular-ﬁltered glucose
(10–13).
Both phlorizin, an O-glucoside, non-
speciﬁc renal glucose reabsorption inhib-
itor, and individuals with SGLT2 genetic
mutations provided early insight into the
potential value of this therapeutic ap-
proach. Phlorizin was shown to reduce
hyperglycemia by inhibiting glucose re-
absorption (14,15); however, clinical ap-
plication was limited by glucosidase
degradation and lack of SGLT2 selec-
tivity. Dapagliﬂozin is highly SGLT2 se-
lective and contains a C-glucoside for
increased in vivo stability, characteris-
tics that prolong half-life and produce
consistent pharmacodynamic activity
(9). Dapagliﬂozin induces steady rates
of glucosuria in healthy volunteers and
type 2 diabetic patients, amounting to
70 g glucose excreted daily (16). In-
dividuals with familial renal glycosuria,
aconditioncausedbygeneticmutations
in SGLT2, have been characterized as
having largely benign phenotypes with
normal life expectancies and no long-
term renal deterioration or known
health consequences (17,18).
This dose-ranging monotherapy
study describes efﬁcacy, safety, and labo-
ratory data for dapagliﬂozin treatment
over 12 weeks. The results support appli-
cation of SGLT2 inhibition as a unique
insulin-independent approach to im-
prove hyperglycemia and weight status in
type 2 diabetic patients.
RESEARCH DESIGN AND
METHODS— From December 2005
to September 2006, drug-naive type 2 di-
abetic patients, aged 18–79 years, with
A1C 7% and 10%, were recruited at
98 clinical centers in the U.S., 24 in Can-
ada, 8 in Mexico, and 3 in Puerto Rico.
Inclusion criteria included fasting C-
peptide 1.0 ng/ml, BMI 40 kg/m
2,
andrenalstatusasfollows:glomerularﬁl-
tration rate 60 ml/min per 1.73 m
2,s e -
rum creatinine 1.5 mg/dl (men)/1.4
mg/dl (women), and urine microalbu-
min/creatinine ratio 300 mg/g.
Thiswasaprospective,12-week,ran-
domized, parallel-group, double-blind,
placebo-controlled study, with a 2-week
diet/exercise placebo lead-in and 4-week
follow-up (Fig. 1). Patients were ran-
domly assigned equally to once-daily
dapagliﬂozin (2.5, 5, 10, 20, or 50 mg),
metformin XR (750 mg force-titrated at
week 2 to 1,500 mg) (therapeutic bench-
mark), or placebo. Safety and efﬁcacy
were assessed at all study visits. Patients
with fasting plasma glucose (FPG) 240
mg/dl at weeks 4 and 6, 220 mg/dl at
week 8, or 200 mg/dl at week 10 were
discontinued from the study and were el-
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agents. The study was conducted pursu-
anttotheDeclarationofHelsinkiandwas
approved by institutional review boards/
independent ethics committees at partic-
ipating sites. Patients provided written
informed consent before enrollment.
The primary objective was to com-
pare mean A1C change from baseline for
each dapagliﬂozin group versus placebo
after12weeks.Secondaryobjectiveswere
comparisons of dapagliﬂozin versus pla-
cebo for FPG change from baseline, dose-
dependent trends in glycemic efﬁcacy,
proportion of patients achieving A1C
7%, and change in 24-h urinary glu-
cose-to-creatinine ratio.
Measurements
Study visits occurred at screening; days
14and1;weeks1,2,4,6,8,10,and12;
and follow-up weeks 14 and 16. Fasting
blood and urine samples were collected
after a minimum 10-h fast. During oral
glucose tolerance testing, blood was
drawnat0,30,60,120,and180minafter
an oral glucose challenge (75 g). Samples
werecentrallyassessed(QuintilesLabora-
tories, Smyrna, GA). Glucose area under
the curve (AUC) was calculated by trape-
zoidal methodology. Vital signs, brief
physical examination, and adverse event
assessment were performed at each visit.
Complete physical examination and elec-
trocardiogramswereperformedatlead-in
and week 12.
Adverse events were summarized by
preferred term (Medical Dictionary for
Regulatory Activities [MedDRA], version
10). Safety topics of special interest were
summarized by interest categories.
Statistical analyses
Fifty patients per treatment group pro-
vided 82% power to detect a mean 0.7%
difference in A1C between dapagliﬂozin
groups and placebo, assuming 1% SD.
Comparisons between dapagliﬂozin and
placebowereperformedatthe0.012level
using Dunnett’s adjustment so that over-
all type 1 error rate was controlled at 0.05
signiﬁcance. Statistical analyses were per-
formed on all randomly assigned and
treated patients. Missing values were im-
puted by last observation carried forward
(LOCF).Week12primaryandsecondary
efﬁcacy analyses for A1C, FPG, and 24-h
urinary glucose-to-creatinine ratio were
performed by ANCOVA with treatment
group as the effect and baseline value as
covariate. Linear trend tests were per-
formed to assess dose-response relation-
ships among dapagliﬂozin groups for
A1Cchangefrombaselineafter12weeks.
Fisher’s exact test was used to compare
the proportion of subjects achieving A1C
7.0%betweendapagliﬂozingroupsand
placebo.
RESULTS— A total of 389 patients
were randomly assigned to receive dapa-
gliﬂozin, metformin, or placebo (Fig. 1);
348 completed week 12, and 41 discon-
tinued. The most common reason for dis-
continuation was withdrawal of consent
(12 patients). Baseline demographics and
disease characteristics were similar
among all groups (Table 1).
At week 12, all dapagliﬂozin groups
achieved signiﬁcant reductions in mean
A1C change from baseline versus placebo
(Fig. 2A and Table 2). Adjusted mean re-
ductions ranged from 0.55 to 0.90%
(dapagliﬂozin), 0.18% (placebo), and
0.73% (metformin). No log-linear
dose-response relationship was demon-
strated (Ptrend  0.41).
FPG reductions were apparent by
week 1 in all dapagliﬂozin groups. By
week 12, adjusted mean FPG reductions
Figure 1—Patient disposition and study design. T2DM, type 2 diabetic.
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6 mg/dl (placebo), and 18 mg/dl
(metformin), demonstrating dose-related
FPG decreases and statistically signiﬁcant
reductions in the 5- to 50-mg dapagliﬂo-
zin groups versus placebo (Fig. 2B). Ad-
justed mean postprandial plasma glucose
(PPG) AUC reductions from baseline were
7,053 to 10,149 mg   min
1   dl
1
(dapagliﬂozin), 3,182 mg   min
1   dl
1
(placebo), and 5,891 mg   min
1  
dl
1 (metformin) (Fig. 2C and Table 2).
Proportions of patients achieving
A1C 7% at week 12 ranged from 40 to
59% (dapagliﬂozin), 32% (placebo), and
54% (metformin). The comparison ver-
sus placebo was statistically signiﬁcant
only for the 50-mg group (P  0.01).
Urinary glucose excretion increased
in all dapagliﬂozin groups. Adjusted
mean changes in 24-h urinary glucose-
to-creatinine ratios at week 12 were
32–65 g/g versus 0.2 g/g for placebo
(P  0.001 for each dapagliﬂozin
group) (Fig. 2D and Table 2). Total
mean urinary glucose excreted per 24 h
at week 12 ranged from 52 to 85 g with
dapagliﬂozin (Table 2).
Total body weight reductions oc-
curred in all groups (Fig. 3A). Mean per-
cent reductions at week 12 were 2.5 to
3.4% (dapagliﬂozin), 1.2% (pla-
cebo), and 1.7% (metformin) (Fig. 3B
and Table 2). More patients achieved
5% reductions with dapagliﬂozin
(range 15.3–29.1%) than with placebo
(7.7%); the proportion with metformin
was 16.1%. Mean percent changes in
waistcircumferencewere1.6to3.5%
(dapagliﬂozin), 1.2% (placebo), and
2.2% (metformin).
Generally, adverse events were re-
ported at similar frequencies across all
groups (Table 2). No deaths or drug-
related serious adverse events occurred.
Hypoglycemic events were reported in
6–10%ofdapagliﬂozin-treatedpatients
with no dose relationship, in 4% of pla-
cebo-treatedpatients,andin9%ofmet-
formin-treatedpatients(Table2).There
were no symptomatic hypoglycemic
events with a ﬁngerstick glucose 50
mg/dl.
Relevant adverse events were grouped
into special interest categories. Events re-
lating to each category were pooled (e.g.,
preferred terms “urinary tract infection”
and“cystitis”werepooledas“infectionsof
the urinary tract”) (Table 2). Infections of
the urinary tract were seen in 5–12% of
dapagliﬂozin-treated patients with no
clear dose relationship versus 6% of
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formin-treated patients. Genital infec-
tions were seen in 2–7% of dapagliﬂozin-
treated patients, 0% of placebo-treated
patients, and 2% of metformin-treated
patients.
Hypotensive events were seen in
0–2% of dapagliﬂozin-treated patients
versus2%ofplacebo-treatedpatientsand
4% of metformin-treated patients. De-
creased blood pressure was observed in
all dapagliﬂozin groups (Table 2). Mean
changes from baseline in supine systolic
blood pressure (sBP) at week 12 ranged
from 2.6 to 6.4 mmHg with no clear
dose relationship. Similar changes oc-
curred for standing sBP. Changes in dia-
stolic blood pressure (dBP) and heart rate
were small and inconsistent across dapa-
gliﬂozin groups.
The diuretic effect of dapagliﬂozin
was assessed by 24-h urine volume, he-
matocrit, and serum blood urea nitrogen
(BUN) and creatinine (Table 2). Small
dose-related increases in 24-h urine vol-
umes (range 107–470 ml above baseline
of 1.8–2.2 l) were demonstrated at week
12. Increases in hematocrit were also
dose-related (range 1.5–2.9%). There
were small changes from baseline in se-
rum BUN and no change in serum creat-
inine at week 12 across dapagliﬂozin
doses. Mean percent increases at week 12
in the BUN-to-creatinine ratio ranged
from 10.4 to 18.3%, with no apparent
dose relationship. Changes in urine vol-
ume, hematocrit, and BUN-to-creatinine
ratio returned toward baseline during fol-
low-up. There was no clinically meaning-
ful change in estimated glomerular
ﬁltration rate (Modiﬁcation of Diet in Re-
nal Disease formula) (19) in any group.
All groups experienced a small decrease
in 24-h creatinine clearance.
A small increase of 0.1 mEq/l above
the baseline mean (1.7 mEq/l) in serum
magnesium and a larger relative decrease
of 1.0 mg/dl below the baseline mean
(5.5 mg/dl) in serum uric acid were ob-
served, returning toward baseline after
discontinuation of dapagliﬂozin. Serum
phosphate increased in a dose-related
manner for doses5 mg (range 0.01 to
	0.24 mg/dl from baseline of 3.6–3.8
mg/dl), although these changes were not
statistically different from placebo (0.08
mg/dl) (Table 2). There were no clinically
relevant mean changes from baseline in
serum sodium, potassium, and calcium
(Table 2).
With respect to bone metabolism, se-
rum 1,25-dihydroxyvitamin D and 25-
hydroxyvitamin D values were
unchanged from baseline. Mean changes
in the 24-h urinary calcium-to-creatinine
ratio were similar to those with placebo.
Small increases in mean parathyroid hor-
mone concentrations (range 0.6–7.0
pg/mlabovebaselineof31.1–35.0pg/ml)
were noted, which were generally greater
than the 0.8 pg/ml increase for placebo.
There was no clear treatment effect of
dapagliﬂozin on fasting lipid parameters
in this 12-week study.
CONCLUSIONS — Glucose reab-
sorption by the kidney is necessary from
an evolutionary standpoint to retain calo-
Figure 2—Changes in glycemic parameters. A: Adjusted mean change from baseline in A1C at week 12 (LOCF). B: Mean change in FPG over time
(observed values). C: Adjusted mean change from baseline in postprandial glucose area under the curve (AUC) during a 75-g oral glucose tolerance
test at week 12 (LOCF). D: Change from baseline in 24-h urinary glucose (grams) normalized for urinary creatinine (grams) at week 12 (LOCF).
Displayed are means and 95% CIs (A, B, and D). When statistical signiﬁcance was achieved with dapagliﬂozin groups compared with placebo,
Dunnett’s multiplicity adjustment was used. P values versus placebo at week 12.
List and Associates
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diabetes by contributing to perpetuation
of hyperglycemia and caloric excess. Par-
adoxically, the glucose resorptive capac-
ity of the kidney may increase in type 2
diabetes (20). Therefore, limiting renal
glucose reabsorption through the inhibi-
tion of SGLT2 represents a new approach
to treating hyperglycemia in type 2 dia-
betic patients.
This study provides evidence that in-
ducing controlled glucosuria through se-
lective SGLT2 inhibition improves
hyperglycemia consistently over 12
weeks of treatment in type 2 diabetic pa-
tients. Dapagliﬂozin produced decreases
in A1C, FPG, and PPG after 12 weeks,
with reductions in FPG apparent by week
1. Changes in FPG were dose-related;
however, there was little evidence of a
dose response for either PPG or A1C.
These observations apparently reﬂect an
intrinsic property of dapagliﬂozin as an
SGLT2 inhibitor. The impact of SGLT2
inhibition was relatively greater on PPG
thanonFPG,withrenalglucoseexcretion
acting as a relief valve to blunt postpran-
dial hyperglycemia. Even the lowest
dapagliﬂozin dose (2.5 mg) produced a
near-maximal effect on PPG, consistent
with reductions observed in a clinical
ward study (16). In contrast, the effect on
FPG, measured at the trough drug con-
centration, was dose-ordered and corre-
sponded to expected residual trough
pharmacodynamic activity (16).
Dapagliﬂozin exhibited a diuretic ef-
fect,withsmalldose-dependentincreases
in urine volume equivalent to 0.3–1.5
voids/day, small increases in BUN, and
smalldose-dependentincreasesinhemat-
ocrit. No clinical safety signals for dehy-
dration were observed. The observed
decrease in sBP was consistent with a di-
uretic action. The relevance of this diure-
sis in type 2 diabetic patients, who often
require diuretics for controlling hyper-
tension (21), warrants further investiga-
tion. Although no effect on renal function
was observed, longer-term studies and
exploratory renal biomarker assessments
are being undertaken.
Dapagliﬂozin-treated patients experi-
enced total body weight reductions. Vet-
erinary literature suggests that chronic
administration of phlorizin in lactating
cows induces lipolysis (22), and dapagli-
ﬂozin in obese rats induces reduced adi-
posity (23). During treatment, all doses
induced progressive weight reductions,
consistent with steady caloric loss
through glucosuria. Weight loss was
more pronounced during week 1 with
dapagliﬂozin, particularly at higher
doses. This observation, coupled with a
rapid partial rebound in weight after dis-
continuation of higher doses, suggests
that diuresis may contribute to some
weight loss. Overall, it appears likely that
acute weight reduction during week 1
represents ﬂuid loss, which may also re-
sult in lower sBP, whereas continued
gradual weight loss represents decreased
fat mass. Longer-term clinical and body
composition studies will help to establish
therelativecontributionofdiuresisversus
adiposity reduction to total weight loss.
Daily dapagliﬂozin was well tolerated
withnomajordifferenceinadverseevents
across treatment groups. The hypoglyce-
mia experience supports the potential for
dapagliﬂozin to achieve meaningful gly-
cemic efﬁcacy with relatively low hypo-
glycemic risk. The number of reported
urinarytractinfectionswassimilaramong
dapagliﬂozin, metformin, and placebo
groups and is consistent with rates re-
ported in type 2 diabetic patients (24).
The incidence of genital infections was
higher with dapagliﬂozin versus placebo,
especially at higher doses, but without
statistical signiﬁcance for comparison. Of
note is the lower rate of genital infections
reported for placebo group patients than
previouslyreportedfortype2diabeticpa-
tients (25).
Dapagliﬂozin increased serum phos-
phateathigherdoses,andallarmsinclud-
ing placebo and metformin demonstrated
increased serum parathyroid hormone.
Additional data are needed to understand
the long-term effects of chronic glucos-
uria and dapagliﬂozin treatment on skel-
etal metabolism.
This study demonstrated the clinical
efﬁcacy of inhibiting renal glucose reab-
sorption with dapagliﬂozin in type 2 dia-
betic patients and relative safety across
numerous doses. Our results suggest that
dapagliﬂozin, as the ﬁrst in a new class of
SGLT inhibitors, can improve glycemic
and weight status of type 2 diabetic
patients. Although we evaluated mono-
therapy, the insulin-independent mecha-
Figure3—Percentchangesinweight.A:Percentchangefrombaselineinweightoverthe12-week
treatmentperiodand4-weekfollow-upperiod(observedvalues).B:Adjustedmeanpercentchange
from baseline in weight after 12 weeks of treatment (LOCF). Displayed are means and 95% CIs.
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other type 2 diabetes agents that act
through insulin signaling pathways and
thus enhance combination therapy. Al-
though human genetic case reports are
reassuring, the chronic effects of phar-
macologically induced glucosuria are
unknown and require long-term assess-
ment. On the basis of evidence to date,
further clinical study of dapagliﬂozin is
warranted to develop a more deﬁnitive
beneﬁt/risk proﬁle for this novel thera-
peutic agent.
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